These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38288442)

  • 1. Structure of human GPR119-G
    Li R; Qian Y; Wang J; Han Z; Ye S; Wu S; Qiao A
    Front Pharmacol; 2024; 15():1310231. PubMed ID: 38288442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation and signaling mechanism revealed by GPR119-G
    Qian Y; Wang J; Yang L; Liu Y; Wang L; Liu W; Lin Y; Yang H; Ma L; Ye S; Wu S; Qiao A
    Nat Commun; 2022 Nov; 13(1):7033. PubMed ID: 36396650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR119 agonists for the treatment of type 2 diabetes.
    Jones RM; Leonard JN; Buzard DJ; Lehmann J
    Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
    Li H; Fang Y; Guo S; Yang Z
    Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
    [No Abstract]   [Full Text] [Related]  

  • 5. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
    Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review.
    Nema P; Asati V; Kendya P; Gupta T; Agarwal S; Kori S; Kashaw V; Iyer AK; Kashaw SK
    Mini Rev Med Chem; 2023; 23(21):2008-2040. PubMed ID: 36861804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
    Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
    Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
    Kubo O; Takami K; Kamaura M; Watanabe K; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Kitazaki T; Murata T; Sato K
    Bioorg Med Chem; 2021 Jul; 41():116208. PubMed ID: 34010766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.
    Engelstoft MS; Norn C; Hauge M; Holliday ND; Elster L; Lehmann J; Jones RM; Frimurer TM; Schwartz TW
    Br J Pharmacol; 2014 Dec; 171(24):5774-89. PubMed ID: 25117266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119.
    Xu P; Huang S; Guo S; Yun Y; Cheng X; He X; Cai P; Lan Y; Zhou H; Jiang H; Jiang Y; Xie X; Xu HE
    Nat Struct Mol Biol; 2022 Sep; 29(9):863-870. PubMed ID: 35970999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained wash-resistant receptor activation responses of GPR119 agonists.
    Hothersall JD; Bussey CE; Brown AJ; Scott JS; Dale I; Rawlins P
    Eur J Pharmacol; 2015 Sep; 762():430-42. PubMed ID: 26101059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU
    Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameterization of the GPR119 Receptor Agonist AR231453.
    Hamilton J; Kotsikorou E
    J Comput Chem; 2018 Jan; 39(1):35-41. PubMed ID: 29023843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.